Table 1 Patient characteristics
From: Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda
Inclusion | Study groups | ||
|---|---|---|---|
Pregnant women treated with AL for malaria (n = 1072) | Pregnant women without malaria (n = 978) | P-value | |
Followed prospectively at AL treatment | 358 (33.4%%) | 885 (90.5%) | |
Recruited at second AL treatment during this pregnancy | 6 | ||
Recruited after recovery from malaria but before delivery | 513 (47.9%%) | n/a | |
Recruited after delivery | 188 (17.5%) | 93 (9.5%) | |
Delivered during treatment | 7 (0.7%) | n/a | |
Median age (min–max, yrs) | 26.0 (17–48) | 27.0 (16–47) | 0.091 |
Gravidity | 0.002 | ||
Primigravidae | 320 (29.9%) | 210 (21.5%) | <0.001 |
Multigravidae | 712 (66.4%) | 730 (74.6%) | |
Unknown | 40 (3.7%) | 38 (3.9%) | |
Median gravidity (min–max) | 2 (1–12) | 3 (1–11) | <0.001 |
Median parity (min-max) | 1 (0–10) | 2 (0–9) | <0.001 |
Mean gestational age (95% CI, weeks) | 25.8 (25.3, 26.4; n = 1052) | 28.5 (28.0, 29.0; n = 973) | <0.001 |
Trimester | |||
First | 96 (9.0%) | 43 (4.4%) | <0.001 |
Second | 434 (40.5%) | 341 (34.9%) | |
Third | 542 (50.6%) | 594 (60.7%) | |
Reported Medical History | NS | ||
1st AL treatment during this pregnancy >56 days before 2nd treatment | 4 | ||
Quinine treatment during this pregnancy | 6 | ||
> 56 d before AL | 1 | ||
Just before delivery, > 56 after AL | 1 | ||
Intermittent Presumptive Treatment with SP | 242 (23.4%; n = 1032) | 265 (28.2%; n = 940) | 0.016 |
Hypertension | 0 | 1 (0.1%) | |
Diabetes mellitus | 1 (0.09%) | 1 (0.1%) | |